Funding for this research was provided by:
Xi’an Janssen Pharmaceutical Ltd., Beijing, China (-)
Received: 19 February 2019
Accepted: 29 July 2019
First Online: 16 August 2019
Ethics approval and consent to participate
: This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The Institutional Review Board at each study site approved the trial design.(see the REMICADECRD4018 CSR IRB-IEC List).All the eligible patients provided written informed consent before participating in the study.
: Not applicable.
: This work was supported by Xi’an Janssen Pharmaceutical Ltd., Beijing, China. The funding body had a role in data analysis and data interpretation. No other competing interests exist.